We found that the cancer patient treatment-relevant relation between PELO and FOCAD, or the experimentally identified interactions between SLC7A2 and SLC7A1, or SLC7A6 and SLC7A1 were best predicted upon combinatorial normalization (Appendix Fig. S5E; Dataset EV1) (Borck et al, 2025; Wolf et al, 2024). The gene discussed is SLC7A6; the disease is cancer.